ANDA 76105, held by Barr. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 76105 (Tri-Legest Fe), held by Barr, was first approved by FDA on Oct 26, 2007, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Tri-Legest Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets [not USP]) is indicated for the prevention of pregnancy in women who elect to use combined oral contraceptives as a method of contraception. Tri-Legest Fe is indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to combined oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 26, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tri-Legest Fe0.02MG,0.03MG,0.035MG;1MG,1MG,1MG · tablet;oral-28 | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Jun 18, 2025 | Supplement 20Labeling · Standard review | Approved | None posted |
| Oct 15, 2021 | Supplement 13Labeling · Standard review | Approved | None posted |
| Aug 6, 2021 | Supplement 8Labeling · Standard review | Approved | None posted |
| Aug 6, 2021 | Supplement 9Labeling · Standard review | Approved | None posted |
| Oct 26, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters